Introduction: Monocarboxylate transporter 4 (MCT4) is the main exporter of lactate out of cells. It is also a critical component in the glycolytic metabolism of cancer cells. In this study, stromal MCT4 in oral SCC was correlated with risk of recurrence (ROR), extent of primary tumor (pT) and nodal metastasis (pN), perineural invasion (PNI), lymphovascular invasion (LVI), HPV status, extracapsular extension (ECE) and positive margin. Methods: Clinical data were collected for 86 consecutive patients with oral HNSCC. Tissue microarrays (TMA) were constructed from paraffin blocks of resection specimens and stained for MCT4. Immunohistochemistry (IHC) staining was assessed and quantified by digital image analysis with Aperio software. Using a colocalization algorithm we assessed the intensity of staining and the percentage of positive cells in the tumoral stromal cells. Correlations of MCT4 expression with clinicopathological features and survival were studied. Results: Increased IHC staining for MCT4 was strongly associated with an increased risk of recurrence, OR 1.96 (95%CI: 1.17-3.40), presence of PNI, OR 2.25 (95%CI: 1.33-3.95), higher pT, OR 1.68 (95%CI: 0.99-2.89), higher pN, OR 2.07 (95%CI: 1.25-3.57) and presence of LVI, OR 2.21 (95%CI: 1.11-4.67). We didn't find any significant association between stromal MCT4 expression and HPV status, presence of ECE or positive margin. Conclusions: This study demonstrates that MCT4, a marker of glycolysis in cancer-associated stroma, is highly expressed in oral SCC. The IHC staining pattern of stromal MCT4 suggests that high MCT4 expression appears to be a useful marker for tumor progression and prognosis. We propose MCT4 serves as a new prognostic factor in oral SCC and can act as a potential therapeutic target marker considering pharmacological development of MCT4 inhibitors.
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INTRODUCTION
Metabolic dysregulation is a critical process that leads to tumorigenesis and altering the tumor microenvironment in many cancers. Recent studies suggest that distinct metabolic compartments exist in HNSCC and other cancers. That metabolic coupling between compartments promotes tumorigenesis. Normal cells rely on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes where tumor cells are highly glycolytic despite the presence of oxygen. This phenomenon is called "the Warburg effect". A Reverse Warburg Effect has been recently showed that tumor cells take advantage of the adjacent non-cancerous stromal cells to become glycolytic and the metabolic products such as lactate and pyruvate are then shuttled by monocarboxylate transporters (MCT1 and MCT4) to provide fuel for tumor growth and aggressive behavior. Peritumoral staining of MCT4, as a functional biomarker, has been associated with poor outcomes in HNSCC. The full significance of metabolic coupling has not yet been cleared for oral cavity squamous cell carcinoma. 
STROMAL MONOCARBOXYLATE TRANSPORTER MCT4 IS A POOR PROGNOSTIC FACTOR IN SQUAMOUS CELL CARCINOMA

METHODS
After IRB approval, records of 86 consecutive patients treated surgically for oral cavity squamous cell carcinoma were reviewed. Clinical data were collected for each patient, and each primary tumor sample was processed onto a tissue microarray (TMA) for immunohistochemistry (IHC) staining. IHC staining was performed for MCT4 antibody (Santa Cruz Biotechnology) . Intensity of IHC staining for each sample was acquired using digital pathology interpretation by Aperio. Intensity scores were compared against clinical data to identify potential biomarker for favorable or unfavorable tumor behavior.
RESULTS
Patient demographics and characteristics are shown in Table 1 Figure 2 ).
Figure 2. OR plots
CONCLUSION
Oral cavity squamous cell carcinoma showed strong MCT4 staining pattern that suggests metabolic compartmentalization in peritumoral stroma, which is associated with disease recurrence and other poor prognostic indicators; thus they may serve as a functional biomarkers for more aggressive oral cavity cancers. Furthermore, therapies to target metabolic coupling may be beneficial in patients with oral cavity cancer. 
